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with a Lynch Syndrome patient. Willingness to prescribe 
was 91.3% at 100  mg, and declined to 81.8% at 300  mg 
and 62.3% at 600  mg (p < 0.001). In multivariable analy-
ses, willingness to prescribe (600  mg) was higher among 
GPs ≥50 years (OR 1.46, 95% CI 1.03–2.07), more expe-
rienced GPs (OR 1.50, 95% CI 1.10–2.04), GPs who were 
aware of the cancer preventive effects of aspirin (OR 1.58, 
95% CI 1.20–2.09), and those who reported seeing a Lynch 
Syndrome patient in practice (OR 1.44, 95% CI 1.01–2.05, 
p = 0.045). GPs report limited awareness of Lynch Syn-
drome and the preventive effects of aspirin among carriers. 
To ensure the optimal dose identified in the CaPP3 trial is 
readily available to patients, prescribing guidance and strat-
egies to educate GPs should be developed.
Keywords Aspirin · Implementation · Lynch Syndrome · 
Preventive therapy · Chemoprevention · Prescribing
Introduction
In the UK, colorectal cancer (CRC) affects over 41,000 
people annually and more than 16,000 people die of the 
disease every year [1]. At a conservative estimate, 3% 
of CRC is attributable to Lynch Syndrome, equating to 
approximately 28,600 cases worldwide per annum [2]. 
Lynch Syndrome, also known as hereditary non-polyposis 
colorectal cancer (HNPCC), is defined in terms of having a 
germline mutation in a DNA mismatch repair gene, includ-
ing MLH1, MSH2, MSH6, or PMS2 [3]. The syndrome is 
characterised by the development of a spectrum of cancers, 
primarily of the colorectum and endometrium at an unusu-
ally young age. Lynch Syndrome affects 1–3 in 1200 peo-
ple in the UK, making it the most common hereditary CRC 
condition [4].
Abstract A dose non-inferiority study comparing 
100 mg, 300 mg and 600 mg of aspirin for cancer preven-
tion among Lynch Syndrome carriers is underway (Colo-
rectal Adenoma/Carcinoma Prevention Programme trial 
3, CaPP3). To guide implementation of the findings, we 
investigated general practitioner (GP) attitudes towards 
aspirin prescribing for Lynch Syndrome carriers. We sur-
veyed 1007 UK GPs (9.6% response rate). Using a within-
subjects design, GPs read a statement on harms and ben-
efits of aspirin and indicated their willingness to prescribe 
aspirin at three doses (100 mg, 300 mg, 600 mg). Approxi-
mately two-thirds (70.8%) of GPs had heard of Lynch Syn-
drome or its associated names, and among those 46.7% 
were aware of the cancer preventive effects of aspirin 
among carriers. Two-thirds (68.1%) of GPs reported feel-
ing comfortable discussing harms and benefits of aspirin 
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There is ongoing interest in the use of aspirin to pre-
vent cancer among carriers of Lynch Syndrome. The 
Colorectal Adenoma/Carcinoma Prevention Programme’s 
second trial (CaPP2) is the only randomised controlled 
trial to compare aspirin (600 mg) against placebo among 
Lynch Syndrome carriers (n = 861) [5]. Intention-to-treat 
analysis failed to show a significant reduction in CRC 
incidence, but secondary analyses using both per protocol 
analysis and taking multiple primary events into account 
reached statistical significance. Participants complet-
ing 2 years of aspirin treatment experienced over a 50% 
reduction in CRC incidence [5]. There was also evidence 
suggesting reduced incidence of other cancers associ-
ated with the syndrome. Aspirin use is associated with 
an age-dependent increased risk of bleeding, particu-
larly gastrointestinal bleeding [6]. The extent to which 
lower doses of aspirin reduce cancer incidence among 
this patient group is unknown. To identify the optimal 
dose for Lynch Syndrome carriers, the CaPP3 trial was 
developed. CaPP3 is a non-inferiority trial comparing 
doses of 100 mg, 300 mg and 600 mg among 2000 Lynch 
Syndrome carriers in the UK. Participants will take 
their allocated dose for 2 years, at which point the study 
will become open-label at the same dose. Results of the 
CaPP3 trial are expected in 2020.
No UK guidance exists on the management of Lynch 
Syndrome patients in clinical genetics, however the Euro-
pean Guidelines for the clinical management of Lynch Syn-
drome recommends offering low-dose aspirin (≤100  mg) 
for the prevention of CRC [7]. Ensuring chemoprevention 
is appropriately prescribed in the National Health Service 
(NHS) is listed as a priority within the Cancer Strategy for 
England [8]. A number of empirical studies and system-
atic reviews have highlighted a failure to translate research 
findings into changes in clinical care. A framework from 
Khoury and colleagues suggests 97% of genomic research 
involves developing successful clinical interventions for 
patients, with little focus on implementing successful 
developments [9]. The remaining 3% of research is directed 
towards evaluating the value of that intervention for clinical 
practice, the development and subsequent use of evidence-
based guidelines by clinicians, and assessing the ‘real 
world’ impact of the intervention.
Attention is therefore required to ensure clinical recom-
mendations developed following successful trial results are 
implemented rapidly. In addition, research should be under-
taken to identify potential barriers to implementing future 
trial results, such as those from the CaPP3 study. Clini-
cian-reported barriers to implementing preventive therapy 
guidelines for breast cancer have been reported [10–12], 
including the unlicensed status of tamoxifen, limited 
knowledge among general practitioners (GPs) and concerns 
about responsibility for prescribing.
As the use of aspirin for Lynch Syndrome carriers is still 
under investigation in clinical trials, it may be premature to 
investigate the role of licencing and care pathways as barri-
ers to GP prescribing. However, knowledge and willingness 
to prescribe in this context are key factors that will affect 
subsequent implementation. Identifying such issues early 
will allow strategies to be developed to address them. In an 
Australian study (n = 181) of genetics professionals, gastro-
enterologists and colorectal surgeons, the majority (78%) 
reported having previously prescribed or recommended 
aspirin for Lynch Syndrome carriers [13]. However, the 
sample was small and unrepresentative, and GP attitudes 
were not investigated. Considering the majority of prescrib-
ing in the UK originates from general practice, this is an 
important group to include within attitudinal surveys in this 
context.
We surveyed a national sample of UK GPs currently 
practising in the NHS. GPs viewed relevant information on 
the topic and were asked a series of survey items investi-
gating awareness of Lynch Syndrome and aspirin and their 
attitudes towards prescribing aspirin. We hypothesised GPs 
would be most willing to prescribe aspirin at lower doses. 
As 600 mg was the dose proven to reduce the risk of CRC 
associated with Lynch Syndrome in the CaPP2 trial [5], we 
investigated the GP characteristics associated with willing-
ness to prescribe at this level. We anticipated a greater will-
ingness to prescribe at the 600 mg dose among GPs who 
were more senior in their practice, had more experience as 
a GP, had prior knowledge of a cancer prevention indica-
tion for aspirin in Lynch Syndrome carriers, and reported 
a special interest in a relevant area. Finally, we aimed to 
report levels of awareness regarding Lynch Syndrome and 
the preventive effects of aspirin among carriers, as well as 
levels of comfort discussing the harms and benefits of aspi-
rin with a Lynch Syndrome patient.
Methods
Sample
We conducted a national survey of GPs practising in the 
UK in April, 2016. Members of the M3 Global Research 
Panel, a private research company, were invited to take part 
in a survey via email. The M3 panel has over 33,000 GP 
members, which covers the vast majority of GPs in the UK. 
However, not all M3 panel members were approached to 
participate in the study. Panel membership is voluntary and 
respondents to surveys are paid for their time and expertise. 
In this instance, respondents were reimbursed £15 per GP.
Respondents were considered eligible if they listed gen-
eral practice as their speciality. GPs practising outside of 
the UK were excluded. The survey company monitored 
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recruitment rates to ensure all four UK nations were rep-
resented proportionately. A quota of 80 GPs from England 
with a role in clinical commissioning was targeted. Com-
missioners are responsible for planning, agreeing and mon-
itoring services within the English NHS. University ethi-
cal approval was granted from the Queen Mary Ethics of 
Research Committee (QMREC1481).
Study procedure and design
GPs were presented with brief information about Lynch 
Syndrome, including the approximate incidence of the syn-
drome in the population and the susceptibility of carriers 
to CRC and other cancers (online appendix). After items 
assessing GP’s awareness of LS, information was presented 
on the evidence for the cancer preventive effects of aspirin 
among this patient group. Specifically, GPs were presented 
with information regarding the outcomes of the CaPP2 trial 
[5], the recommended dose according to European guide-
lines [7], and the current status of the CaPP3 dose-inferior-
ity trial. Respondents were informed of the major adverse 
events that can occur among people taking aspirin, and that 
aspirin was a generally accepted recommendation among 
this population group. Following this information, respond-
ents completed the remaining items. GPs were able to con-
sult the background information on Lynch Syndrome and 
aspirin throughout the items in this section.
The survey was co-designed by the authors of this report. 
Together, they have expertise in behavioural science, health 
policy, statistics, epidemiology, clinical genetics, primary 
care and public health. A draft survey was prepared by 
SS, and the remaining authors provided comments to be 
included in a revision. The survey was informed by a quali-
tative interview study investigating barriers to prescrib-
ing preventive therapy for breast cancer [10]. The inter-
views were done with family history and clinical genetics 
(FHCG) staff (n = 15) and general practitioners (n = 10). 
These data were supplemented by a further six interviews 
to develop the aspirin and Lynch Syndrome items.
Study measures
Awareness of Lynch Syndrome and aspirin for cancer 
prevention
To assess knowledge of Lynch Syndrome, GPs were pro-
vided with some background information and asked, 
‘Before today, had you heard of Lynch Syndrome, HNPCC 
or Muir Torre syndrome?’ Respondents were asked to indi-
cate all that apply or ‘No, hadn’t heard of any’. GPs were 
also asked, ‘Have you ever seen a patient with Lynch Syn-
drome in your practice?’ (‘Yes’, ‘No’, ‘Unsure’).
To assess GPs’ awareness of the preventive effects of 
aspirin among this patient group, they were asked, ‘Before 
today, were you aware aspirin could reduce the risk of can-
cers associated with Lynch Syndrome?’ Response options 
were ‘Yes’ or ‘No’. Respondents were asked, ‘Have you 
ever discussed the use of aspirin with a Lynch Syndrome 
carrier’. Response options were, ‘Yes’, ‘No’ and ‘Unsure’.
Willingness to prescribe
To assess willingness to prescribe aspirin at each of the 
doses tested in the CaPP3 trial, GPs were asked to ‘Imag-
ine the CaPP3 study shows that [100 mg/300 mg/600 mg] 
of aspirin is the optimal dose for reducing the incidence 
of cancer in Lynch Syndrome carriers. How willing would 
you be to prescribe aspirin [100  mg/300  mg/600  mg] for 
a patient with Lynch Syndrome?’ Response options were 
‘Not at all willing’, ‘Probably not willing’, ‘Probably will-
ing’ and ‘Definitely willing’. All respondents answered the 
question for each of the doses. The order in which the three 
doses were presented was randomised to prevent order 
effects. Data were combined to reflect unwilling and will-
ing responses.
Comfort discussing harms and benefits
To assess GPs’ comfort in discussing aspirin with patients, 
respondents were asked, If a patient was recommended to 
take aspirin by a clinician in secondary care, how comfort-
able would you feel discussing the possible benefits and 
harms of aspirin with a Lynch Syndrome carrier? Response 
options were ‘very uncomfortable’, ‘quite uncomfortable’, 
‘quite comfortable’ and ‘very comfortable’. Data were 
combined to reflect feeling comfortable and uncomfortable.
Respondent characteristics
GPs reported their gender, age in 10-year bands, status 
within the practice (‘GP specialist trainee’, ‘GP partner’, 
‘Salaried or locum GP’, ‘GP retainer’ and ‘other’), region 
of practice (England, Scotland, Northern Ireland, Wales), 
year qualified in general practice (<10 years’ experience, 
≥10 years’ experience), special interests (cancer, preventive 
medicine, family history, and genetics) and among those in 
England, their role in commissioning (yes, no).
Statistical analyses
The trend for willingness to prescribe aspirin across the 
three doses was analysed using an extension of the Wil-
coxon rank-sum test [14]. Multivariable logistic regres-
sion adjusting for all GP characteristics was used to test 
for group differences on awareness, comfort discussing the 
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harms and benefits of aspirin, and willingness to prescribe 
at a 600  mg dose. Three multivariable models control-
ling for respondent characteristics tested the relationships 
between awareness of the preventive effects of aspirin for 
Lynch Syndrome, having seen a Lynch Syndrome patient 
in practice, and having heard of Lynch Syndrome with will-
ingness to prescribe at 600 mg as the outcome. There were 
too few individuals reporting a GP status of ‘GP retainer’ 
or ‘other’ to be included in the logistic regression mod-
els, and therefore these individuals were excluded in these 
analyses. Statistical significance was set a priori at p < 0.05. 
Analyses were performed in SPSS version 22 and STATA 
version 12.
Results
Sample overview
In total, 13,764 GPs were emailed an invitation to take part 
with a link to the survey questionnaire, and 1321 started the 
survey (9.6% response rate). A total of 314 were excluded 
because they did not agree to the terms and conditions 
(n = 35), did not complete the survey (n = 143), completed 
the survey after the deadline (n = 35) or failed a data quality 
check undertaken by the survey company (n = 101). Data 
from 1007 GPs were available for analysis.
An overview of the study sample is shown in Table 1. In 
line with national data, the majority of GPs were from Eng-
land (85.6%). Compared with national estimates, respond-
ents were more likely to be salaried or locum GPs (38.5%), 
male (57.8%) and under the age of 50 years (72.3%). 
Over half of the respondents (56.2%) reported more than 
10 years’ experience in general practice. A minority had 
a special interest in cancer (12.4%), preventive medicine 
(14.2%), family history (5.4%) and genetics (3.3%). Almost 
one-fifth (19.1%) of the English GPs reported having a role 
in commissioning.
Awareness of Lynch Syndrome and aspirin for cancer 
prevention
The majority of GPs (62.5%) reported they had not 
seen a patient with Lynch Syndrome in their prac-
tice, and 19.0% were unsure. Approximately one quar-
ter (27.3%) of GPs had heard of Lynch Syndrome, and 
61.2% had heard of HNPCC and 4.0% had heard of 
Muir-Torre Syndrome. Almost one-third (29.2%) of GPs 
had not heard of any of the names for the syndrome. In 
multivariable analysis adjusted for all GP characteris-
tics, GPs were less likely to be aware of any names for 
Lynch Syndrome if they were male (OR 0.69, 95% CI 
0.51–0.94, p = 0.021), working in Scotland (OR 0.53, 
95% CI 0.31–0.88, p = 0.014) and 50 years or older (OR 
0.42, 95% CI 0.30–0.58, p < 0.001).
Among GPs who had heard of Lynch Syndrome or any 
of its associated names, 3.8% reported they had discussed 
the use of aspirin with a Lynch Syndrome carrier. Among 
GPs who had heard of Lynch Syndrome or any of its 
associated names, only 46.7% were aware aspirin could 
reduce the risk of cancers associated with Lynch Syn-
drome. In a multivariable analysis restricted to those who 
were aware of Lynch Syndrome by at least one name, GP 
trainees had higher odds of being aware of the cancer pre-
ventive effects of aspirin than salaried/locum GPs (OR 
3.55, 95% CI 1.00–12.62, p = 0.050). GPs older than 50 
years of age had lower odds of being aware of the pre-
ventive effects of aspirin than their younger counterparts, 
although the effect was of borderline statistical signifi-
cance (OR 0.66, 95% CI 0.43–1.01, p = 0.053).
Table 1  GP Sample and national characteristics (n = 1007)
National data on experience and specialisms were unavailable
Sample (%) National 
data (%) 
[15]
Country
 England 85.6 82.8
 Scotland 7.8 9.8
 Wales 3.9 4.7
 Northern Ireland 2.7 2.7
Occupation
 GP partner 58.4 67.6
 Salaried/locum GP 38.5 21.2
 GP retainers 0.3 0.9
 GP specialist trainee 2.0 10.3
 Other 0.8 –
Gender
 Male 57.8 50.8
 Female 42.2 49.2
Age
 <50 72.3 57.2
 50+ 27.7 38.0
Experience
 0–10 years 43.8 –
 >10 years 56.2 –
Specialisms
 Cancer 12.4 –
 Preventive medicine 14.2 –
 Family history 5.4 –
 Genetics 3.3 –
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Attitudes towards discussing and prescribing aspirin
After reading information describing the preventive effects 
of aspirin among Lynch Syndrome carriers, 68.1% of all 
GPs indicated they would feel comfortable discussing the 
harms and benefits of the drug with a patient. There were 
no GP characteristics associated with reporting comfort 
in a multivariable model. GPs who were aware of the pre-
ventive effects of aspirin among Lynch Syndrome carriers 
were more likely to report feeling comfortable discuss-
ing the harms and benefits of aspirin (OR 1.81, 95% CI 
1.36–2.43, p < 0.001).
As shown in Fig.  1, almost all respondents indicated 
they were probably willing or definitely willing to prescribe 
aspirin at 100 mg (91.3%). There was a graded decline in 
willingness to prescribe aspirin at 300  mg (81.8%) and 
600 mg (62.3%) (p-trend < 0.001).
In multivariable analysis, GPs who were older than 50 
years of age were more likely to report a willingness to pre-
scribe aspirin at 600  mg than their younger counterparts 
(OR 1.46, 95% CI 1.03–2.07, p = 0.033; Table 2). GPs with 
more than 10 years’ experience were also more likely to 
report a willingness to prescribe compared with less expe-
rienced GPs (OR 1.50, 95% CI 1.10–2.04, p = 0.010). In 
the opposite direction of our hypothesis, GPs reporting a 
special interest in family history were less willing to pre-
scribe a 600 mg dose than those without this special inter-
est (OR 0.41, 95% CI 0.21–0.82, p = 0.011). There were no 
differences in willingness to prescribe at the 600 mg dose 
among GPs with special interests in preventive medicine, 
cancer or genetics (p > 0.05).
In further multivariable models controlling for all 
respondent characteristics, awareness of the preven-
tive effects of aspirin among Lynch Syndrome carriers 
(OR 1.58, 95% CI 1.20–2.09, p = 0.001) and having seen 
a Lynch Syndrome patient in practice (OR 1.44, 95% CI 
1.01–2.05, p = 0.045) were associated with a greater will-
ingness to prescribe at the 600 mg dose. Reporting aware-
ness of Lynch Syndrome or any of its alternative names 
Fig. 1  Willingness to prescribe 
aspirin at 100, 300 and 600 mg 
if the dose was shown to be 
optimal in the CaPP3 study (% 
willing) (N = 1007)
91.3
81.8
62.3
50
55
60
65
70
75
80
85
90
95
100
%
100mg
300mg
600mg
Table 2  Willingness to prescribe aspirin (600  mg) for Lynch Syn-
drome by respondent characteristics (n = 1007)
Unwilling Willing OR (95% CI) p-value
Nation
 England 38.3 61.7 Ref Ref
 Scotland 29.1 70.9 1.54 (0.91–2.60) 0.108
 Wales 46.2 53.8 0.69 (0.36–1.34) 0.277
 Northern Ireland 33.3 66.7 1.22 (0.53–2.81) 0.639
GP Status (n = 996)
 GP partner 34.9 65.1 1.13 (0.85–1.50) 0.408
 Salaried/locum GP 41.0 59.0 Ref Ref
 GP retainers – – – –
 GP Specialist 
trainee
55.0 45.0 0.66 (0.26–1.65) 0.371
 Other – – – –
Gender
 Male 35.7 64.3 1.14 (0.87–1.50) 0.339
 Female 40.5 59.5 Ref Ref
Age
 <50 years 41.3 58.7 Ref Ref
 50 years+ 28.3 71.7 1.46 (1.03–2.07) 0.033
Experience
 0–10 years 45.8 54.2 Ref Ref
 >10 years 31.4 68.6 1.50 (1.10–2.04) 0.010
Cancer specialism
 Yes 40.0 60.0 1.02 (0.66–1.59) 0.919
 No 37.4 62.6 Ref Ref
Preventive medicine specialism
 Yes 37.1 62.9 1.23 (0.80–1.89) 0.348
 No 37.8 62.2 Ref Ref
Family history specialism
 Yes 51.9 48.1 0.41 (0.21–0.82) 0.011
 No 36.9 63.1 Ref Ref
Genetics specialism
 Yes 45.5 54.5 1.21 (0.53–2.77) 0.657
 No 37.5 62.5 Ref Ref
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was not associated with willingness to prescribe (OR 1.26, 
95% CI 0.92–1.71, p = 0.151).
Discussion
This national study highlights potential barriers to imple-
menting the eventual findings of the CaPP3 trial in UK pri-
mary care. There was a statistically significant decline in 
willingness to prescribe aspirin for Lynch Syndrome car-
riers across the three doses being tested, with only two-
thirds indicating they would prescribe at the 600 mg dose. 
Depending on the optimal dose identified by the CaPP3 
trial, there could be important health-service barriers to 
implementing these research findings within routine clini-
cal care. Furthermore, the highest quality evidence avail-
able from the CaPP2 study shows a dose of 600  mg is 
effective for cancer prevention in this population [5]. Lynch 
Syndrome patients seeking a 600 mg prescription of aspi-
rin as part of their routine care may experience difficulties 
if seen by one of the significant minority of GPs who are 
reluctant to prescribe.
A barrier to ensuring Lynch Syndrome carriers receive 
appropriate care is likely to be low awareness among GPs 
regarding the syndrome and the preventive effects of aspi-
rin among carriers. Almost one-third of GPs had not heard 
of any names of the syndrome, and HNPCC was the most 
commonly recognised name among those that had. This 
may be problematic because HNPCC does not account for 
cancers at multiple extracolonic sites that are integral to 
Lynch Syndrome. In our data, awareness of the syndrome 
did not necessarily translate to knowledge of the cancer 
preventive effects of aspirin among carriers. Importantly, 
reporting an awareness of the cancer preventive effects of 
aspirin and having seen a Lynch Syndrome patient in clinic 
were associated with a greater willingness to prescribe the 
600  mg dose. While cross-sectional surveys do not allow 
causal inferences, it is possible that increasing awareness of 
preventive therapy in this context could facilitate prescrib-
ing behaviour. The National Institute for Health and Care 
Excellence (NICE), NHS England and the national equiva-
lents may be best placed to take on such awareness-raising 
initiatives.
Educating GPs with regard to aspirin and Lynch Syn-
drome may be important for communicating with patients 
and promoting informed decision-making. Only two-
thirds of GPs reported feeling comfortable discussing the 
harms and benefits of aspirin, and no sub-groups were 
identified as being particularly likely to report discom-
fort. There are currently no NICE national guidelines for 
the management of patients with Lynch Syndrome, which 
may be contributing to low awareness of the potential role 
of aspirin among Lynch Syndrome carriers. In support 
of the Cancer Strategy for England recommendation 7, 
we commend the decision by NICE to develop national 
guidelines for the management of Lynch Syndrome car-
riers [8]. In addition to guidance on screening and diag-
nosis, specific sections on the use of aspirin are needed. 
These guidelines should be updated following the results 
of the CaPP3 trial, which are expected in 2020.
Younger and less experienced GPs were less willing 
to prescribe aspirin in our data, yet were more likely to 
report an awareness of Lynch Syndrome and the cancer 
preventive effects of aspirin. This may suggest GPs grad-
uating recently received more training in clinical genetics 
and preventive medicine. Alternatively, they may be bet-
ter able to recall their training because it occurred more 
recently. Explanations notwithstanding, our observations 
suggest the effectiveness of awareness raising initiatives 
may be greater if they are targeted at older and more 
experienced GPs. Furthermore, our data also suggest 
alternative solutions to address prescribing behaviour 
may be needed for younger GPs who already demonstrate 
high awareness.
One possibility is to create a set care pathway for the 
prescription of aspirin. In a recent online vignette study we 
showed GPs are more willing to continue a tamoxifen pre-
scription for breast cancer preventive therapy if a second-
ary care clinician has made the first prescription, compared 
with if the GP is asked to write the first prescription [11, 
12]. A myriad of factors may be affecting this observation, 
but it suggests that changing health policy to implement 
shared care agreements between primary and secondary 
care may facilitate appropriate prescribing behaviour. In 
practice, this would mean prescriptions for aspirin would 
be initiated by clinical geneticists in secondary care and 
continued by GPs in primary care. However, clinical genet-
icists may be reluctant to prescribe at all [10], and genetic 
counsellors who often manage Lynch Syndrome patients 
do not have prescribing rights.
Anxiety regarding the lack of licence for preventive 
therapy medications more generally has been suggested 
as a major barrier to prescribing [11, 12]. Further research 
is needed to establish if this and other factors could affect 
willingness to prescribe aspirin for Lynch Syndrome. 
Attaining licences is unlikely, as there is no financial incen-
tive for the pharmaceutical industry to undertake the work 
involved to achieve this. One strategy to overcome this bar-
rier is to include cancer prevention as an indication for spe-
cific patient groups within the British National Formulary 
(BNF). The BNF is the primary resource used by UK pre-
scribers when deciding on the appropriateness of a medica-
tion. While the BNF does not have the authority to licence 
a medication, it frequently describes alternative unli-
censed indications for medications. The Access to Medical 
Treatments (Innovation) Act 2016 aimed at securing the 
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repurposing of drugs for innovative purposes may have a 
role [15].
Targeting knowledge via guidance and education is nec-
essary to improve the management of patients and poten-
tial drug side-effects. However, educating GPs is unlikely 
to be sufficient by itself to ensure population wide imple-
mentation of evidence-based practice. Assuming an aver-
age general practice list size of around 7200 patients, most 
practices will have between 6 and 18 people with Lynch 
Syndrome [16]. The majority of people with Lynch Syn-
drome are likely to be unrecognised [17], which is reflected 
in the low proportion of GPs who reported having seen a 
Lynch Syndrome patient in their practice. There are there-
fore further challenges for any strategy to change and habit-
uate clinical practice for a relatively uncommon condition 
which is under-recognised and poorly recorded. A compre-
hensive population-level strategy therefore needs to include 
effective means to identify and code people with Lynch 
Syndrome. The newly launched patient support group, 
Lynch Syndrome UK, perhaps in conjunction with the 
more established cancer charities may be able to influence 
the low level of recognition of this treatable and prevent-
able cancer category.
This study had limitations. The survey data were cross-
sectional which prevents causal inference. Participants were 
recruited from a large online panel, but not all UK GPs are 
affiliated with the company responsible. Panel members 
may be more motivated to participate in research than non-
members, and their survey responses may therefore not be 
generalisable to all primary care clinicians. Furthermore, 
only a small proportion of those who were approached 
agreed to take part in the survey. Attitudes and awareness 
among GPs who did not respond may therefore be differ-
ent from those who participated. While the sample was rep-
resentative with regard to country, respondents were more 
likely to be salaried GPs, male and younger compared with 
British Medical Association data [18]. This may further 
limit generalisability to those groups. Although the vignette 
was designed to mimic a clinical scenario as best as pos-
sible, the outcome data were hypothetical, and prescrib-
ing behaviour may be different within a clinical setting. A 
range of factors can affect decisions to prescribe, including 
knowledge differences in this context, and we could not 
account for all of them within this survey. For example, we 
did not provide exact information on the risk of bleeding 
associated with aspirin use in this population, or alternative 
risk reduction options. Further research is needed to under-
stand the range of factors affecting clinician’s decision-
making regarding aspirin prescribing for Lynch Syndrome 
carriers.
In conclusion, these data from a national sample of UK 
GPs highlight potentially important health-service barriers 
to implementing preventive therapy for Lynch Syndrome 
carriers, following the completion of the CaPP3 trial. 
Approximately one-third of GPs were unwilling to pre-
scribe at the dose already demonstrated to be effective in 
the CaPP2 trial, and a third were uncomfortable discussing 
the harms and benefits of aspirin with a Lynch Syndrome 
carrier. Low awareness among GPs regarding Lynch Syn-
drome and the preventive effects of aspirin among carriers 
was also apparent. Developing national guidelines for the 
management of Lynch Syndrome carriers in tandem with 
campaigns to promote GP awareness and enhance case 
identification could overcome some barriers to prescribing 
and promote adequate communication on the topic. Add-
ing cancer prevention as an indication for aspirin within the 
BNF may further reduce reluctance to prescribe.
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